OncoSil Medical Ltd (AU:OSL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd has successfully raised $5.3 million through a non-renounceable entitlement offer, contributing to a total of $6.8 million in recent funding efforts for their innovative OncoSil™ brachytherapy device for pancreatic cancer treatment. Eligible shareholders were able to subscribe at a rate of 1 new share for every 2 held, with associated long and short-dated options. The funds are earmarked to support the commercialization of the device, which is already approved for use in over 30 countries.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.